Drug name - Inqovi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9567363 OTSUKA Certain compounds, compositions and methods
Oct, 2028

(6 years from now)

US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

CN101827856A OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

CN101827856B OTSUKA 2'-Fluoro--2'-Deoxy-Tetrahydro-Uridine As Cytosine Nucleoside Deaminase Inhibitor
Oct, 2028

(6 years from now)

IN201003209P1 OTSUKA 2 '-Fluoro-2 ' -Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

IN286739B OTSUKA 2'-Flu0R0-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2447272A1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2447272B1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2207786A1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

EP2207786B1 OTSUKA 2'-Fluoro-2'-Deoxytetrahydrouridines As Cytidine Deaminase Inhibitors
Oct, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618075 OTSUKA Certain compounds, compositions and methods Oct, 2028

(6 years from now)

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

Treatment: Method for inhibiting cytidine deaminase by administering cedazuridine; method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG;35MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.